Welcome to our dedicated page for AN2 Therapeutics SEC filings (Ticker: ANTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AN2 Therapeutics, Inc. (Nasdaq: ANTX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. AN2 describes itself as a clinical-stage biopharmaceutical company developing novel small molecule therapeutics from its boron chemistry platform, with programs in Chagas disease, melioidosis, NTM lung disease caused by Mycobacterium abscessus, and oncology targets.
Periodic and current reports such as Forms 10-K, 10-Q, and 8-K provide detail on AN2’s research and development expenses, cash position, and progress across its pipeline. For example, recent Form 8-K filings reference press releases reporting quarterly financial results, including operating expenses and net loss, and describe how the company is advancing clinical trials and collaborations. These documents help investors understand how AN2 funds and prioritizes its infectious disease and oncology programs.
Regulatory filings can also disclose capital structure changes. A Form 8-K describes AN2’s issuance of pre-funded warrants in exchange for common stock to an institutional investor, including key terms such as exercise price and beneficial ownership limitations. Such filings give insight into how the company structures financing while managing ownership thresholds.
On this page, users can access AN2’s annual reports (Form 10-K) and quarterly reports (Form 10-Q) once filed, along with current reports (Form 8-K) that cover material events, collaborations, and financial updates. AI-powered summaries on Stock Titan are designed to highlight the main points in lengthy filings, helping readers quickly identify items related to clinical development, cash runway, or capital transactions without reading every line.
Investors interested in AN2’s ongoing work in Chagas disease, melioidosis, NTM lung disease, tuberculosis collaborations, and oncology targets can use the filings page to review the company’s official disclosures and track how its boron chemistry platform is reflected in its regulatory reporting.
AN2 Therapeutics, Inc. Chief Financial Officer Lucy Day reported a repricing and replacement of stock options on March 19, 2026. She received new stock option grants covering 73,665, 66,000 and 82,300 shares of common stock, each with a $3.91 per-share exercise price, matching the issuer’s closing price that day.
On the same date, options over identical share amounts with higher exercise prices of $6.596, $17.28 and $14.29 were disposed of back to the company. One grant is fully vested, while two grants vest monthly in forty‑eight equal installments starting from March 25, 2022 and January 1, 2023, contingent on continued service. The $3.91 exercise price may revert to the original higher price if the options are exercised or service ends before a defined "Premium End Date."
AN2 Therapeutics, Inc. Chief Development Officer Sanjay Chanda reported compensation-related option changes, not open-market trades. On March 19, 2026, three existing stock option awards were repriced so that each now has an exercise price of $3.91 per share, matching the closing common stock price on the repricing date.
Each repriced award covers stock options to buy common stock in amounts of 66,000, 57,950 and 41,665 shares. The filing shows matching dispositions of the prior higher‑priced options back to the issuer. One option is fully vested, while the others vest monthly over 48 months starting March 25, 2022 and January 1, 2023, subject to continuous service.
The new $3.91 exercise price can revert to the original higher exercise price if, before the "Premium End Date", the repriced options are exercised or employment ends. The Premium End Date is the earliest of September 19, 2027, a change in control, or the reporting person's death or disability.
AN2 Therapeutics director Gilbert Lynn Marks reported a repricing of stock options with no open-market trades in common shares. On March 19, 2026, he acquired several new stock option awards covering common stock at an exercise price of $3.91 per share and simultaneously disposed of older options back to the issuer for the same share amounts.
The footnotes state that $3.91 represents the closing price of AN2 Therapeutics’ common stock on the repricing date and that the options are fully vested. The exercise price will revert to the original higher exercise price if the repriced options are exercised or if his service ends before the defined “Premium End Date.”
AN2 Therapeutics director Aziz Kabeer reported a repricing of stock options. On March 19, 2026, he received two grants of stock options for 20,724 and 23,742 shares of common stock, each with a new exercise price of $3.91 per share, matching the closing market price that day.
At the same time, he disposed of the same numbers of older options back to the company that had higher exercise prices of $17.28 and $5.91 per share. The repriced options are fully vested and remain subject to a "Premium End Date" that can cause the exercise price to revert to the original level if certain events occur before September 19, 2027.
AN2 Therapeutics director Patricia A. Martin reported a repricing of several stock options on March 19, 2026. She disposed of three existing options to purchase 24,999, 10,362 and 23,742 shares of common stock at exercise prices of $6.596, $17.28 and $5.91 per share, respectively, and received new, fully vested options for the same share amounts at an exercise price of $3.91 per share.
According to the board-approved terms, the $3.91 exercise price equals the closing stock price on the repricing date and will revert to each option’s original exercise price if the repriced option is exercised or her service ends before the “Premium End Date,” defined as the earliest of September 19, 2027, a change in control, or her death or disability.
AN2 Therapeutics director Margaret M. FitzPatrick reported a board-approved repricing of stock options on the company’s common stock. On March 19, 2026, existing options were surrendered to the issuer and replaced with new fully vested options covering the same number of shares at an exercise price of $3.91 per share.
The repricing keeps all other terms unchanged, except that the exercise price will revert to the original higher level if the repriced options are exercised, or if her service ends, before the “Premium End Date.” The Premium End Date is the earliest of September 19, 2027, a change in control, or her death or disability.
AN2 Therapeutics director Stephanie Wong reported a repricing of multiple stock options on the company’s common stock. On March 19, 2026, she was granted new stock options covering 24,999, 10,362 and 23,742 shares at an exercise price of $3.91 per share, matching the closing market price that day. In corresponding transactions, options over the same numbers of shares with higher exercise prices of $6.596, $17.28 and $5.91 were surrendered to the company.
According to the footnotes, the repriced option is fully vested. The $3.91 exercise price will be increased back to the original exercise price if, before the stated “Premium End Date,” the repriced option is exercised or Wong’s service with the company ends.
AN2 Therapeutics director Joseph S. Zakrzewski reported a board-approved repricing of his stock options. On March 19, 2026, existing options to buy common stock with higher exercise prices were surrendered to the company and replaced with new fully vested options at an exercise price of $3.91 per share.
The new options cover multiple grants of stock options (rights to buy common stock) with expiration dates ranging from April 29, 2031 to June 6, 2033. The filing reflects compensation-related adjustments only and does not show any open-market purchases or sales of AN2 Therapeutics common stock.
AN2 Therapeutics, Inc. reported that officer Joshua M. Eizen had certain stock options repriced on March 19, 2026. He received new options to purchase 92,000 and 50,150 shares of common stock at an exercise price of $3.91 per share, replacing prior options for the same share amounts with higher exercise prices of $17.88 and $14.29.
The footnotes explain that the new exercise price equals the closing market price on the repricing date and that vesting schedules remain as previously set. The filing shows no open-market purchases or sales of common stock, only compensation-related option grants and corresponding cancellations back to the issuer.
AN2 Therapeutics director Melvin K. Spigelman reported a board-approved repricing of his stock options on March 19, 2026. He received three fully vested stock option awards for 16,941, 10,362 and 23,742 underlying common shares at a new exercise price of $3.91 per share, while surrendering an equal number of existing options with higher exercise prices of $9.308, $17.28 and $5.91.
The repriced options keep their original terms except for the exercise price. If any repriced option is exercised, or his service ends, before the “Premium End Date” (the earliest of September 19, 2027, a change in control, or his death or disability), the exercise price reverts to the original higher level. These are compensation-related derivative adjustments, not open-market stock purchases or sales.